In a clinical trial of 40 patients with nasopharyngeal carcinoma, DNAzyme specifically targeted at the LMP-1 mRNA lead to the downregulation of LMP-1 expression and an enhanced radiosensitivity together with short-term tumor regression [76]. The gene discussed is PDLIM7; the disease is nasopharyngeal carcinoma.